Amylyx ALS drug fails crucial study, putting company’s future in doubt
Bio Pharma Dive
MARCH 8, 2024
The results have led Amylyx to pause promotion of Relyvrio and potentially pull it from the market in the coming weeks, a major blow to the company and ALS patients.
Let's personalize your content